SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin.
作者： Ju-Hwa Kim , Tae Hyung Kim , Han Sung Kang , Jungsil Ro , Hyung Sik Kim
DOI: 10.1016/J.BBRC.2009.07.036
关键词:
摘要: We identified four breast cancer cell lines and one stomach line resistant to the cytotoxic effects of doxorubicin (DOX) examined their sensitivity other chemotherapeutic agents. SP600125, an inhibitor Jnk pathway, reduced cellular viability all five DOX-resistant lines. Jnk1 siRNA also in which it was tested. Similar results were produced vivo mouse model, volume tumors derived from more effectively by treatment with SP600125 than DOX, whereas those a DOX-sensitive only DOX treatment. Overall, these may contribute development treatments for patients tumors.
elsevier.com
sci-hub.se 参考文章(24)
Yingmei Liu, Barbara M. Mueller, Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochemical and Biophysical Research Communications. ,vol. 344, pp. 1263- 1270 ,(2006) , 10.1016/J.BBRC.2006.04.005
Michiaki Kohno, Jacques Pouyssegur, Targeting the ERK signaling pathway in cancer therapy Annals of Medicine. ,vol. 38, pp. 200- 211 ,(2006) , 10.1080/07853890600551037
B. L. Bennett, D. T. Sasaki, B. W. Murray, E. C. O'Leary, S. T. Sakata, W. Xu, J. C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, S. S. Bhagwat, A. M. Manning, D. W. Anderson, SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase Proceedings of the National Academy of Sciences of the United States of America. ,vol. 98, pp. 13681- 13686 ,(2001) , 10.1073/PNAS.251194298
Aman U. Buzdar, Gabriel N. Hortobagyi, Francisco J. Esteva, Vicente Valero, Lajos Pusztai, Laura Boehnke‐Michaud, Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond Oncologist. ,vol. 6, pp. 133- 146 ,(2001) , 10.1634/THEONCOLOGIST.6-2-133
C.E. Humber, J.F. Tierney, R.P. Symonds, M. Collingwood, J. Kirwan, C. Williams, J.A. Green, Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration Annals of Oncology. ,vol. 18, pp. 409- 420 ,(2006) , 10.1093/ANNONC/MDL417
Christiane Knuefermann, Yang Lu, Bolin Liu, Weidong Jin, Ke Liang, Ling Wu, Mathias Schmidt, Gordon B Mills, John Mendelsohn, Zhen Fan, HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells Oncogene. ,vol. 22, pp. 3205- 3212 ,(2003) , 10.1038/SJ.ONC.1206394
Steven Grant, Cotargeting survival signaling pathways in cancer Journal of Clinical Investigation. ,vol. 118, pp. 3003- 3006 ,(2008) , 10.1172/JCI36898
Mehmet Alper Arslan, Ozgur Kutuk, Huveyda Basaga, Protein Kinases as Drug Targets in Cancer Current Cancer Drug Targets. ,vol. 6, pp. 623- 634 ,(2006) , 10.2174/156800906778742479
Fang Li, Li Meng, Hui Xing, Jianfeng Zhou, Shixuan Wang, Lei Huang, Gang Xu, Huaishi Zhu, Yunping Lu, Ding Ma, Essential role of c-Jun-NH2-terminal kinase on synergy induction of apoptosis by TRAIL plus ADM in ADM resistant MCF-7/ADM cells. Apoptosis. ,vol. 11, pp. 1239- 1246 ,(2006) , 10.1007/S10495-006-7494-8
John L. Nitiss, DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Current opinion in investigational drugs. ,vol. 3, pp. 1512- 1516 ,(2002)